Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Haffner

Showing results (101-110 of 169) with videos related to

Pageof 17
Sort By:
Journal of the National Cancer Institute|November 20, 2024
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabelingYibai Zhao, Roman Gulati, Zhenwei Yang, et al.
The American Journal of Pathology|October 29, 2022
Genomic Characterization of Prostatic Basal Cell CarcinomaJin-Yih Low, Minjeong Ko, Brian Hanratty, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Determining preclinical safety of Aclarubicin in pediatric malignanciesDarleen S Tu, Aaron K Olson, Kimberly S Waggie, et al.
Cancer Research Communications|December 19, 2023
FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-genomic Features of Prostate CancerOluwademilade Dairo, Lia DePaula Oliveira, Ethan Schaffer, et al.
Molecular Cancer Research : MCR|October 16, 2019
Functional Loss of <i>ATRX</i> and <i>TERC</i> Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer CellsMindy K Graham, Jiyoung Kim, Joseph Da, et al.
The Journal of Clinical Investigation|October 19, 2013
Tracking the clonal origin of lethal prostate cancerMichael C Haffner, Timothy Mosbruger, David M Esopi, et al.
Pediatric Blood & Cancer|November 27, 2025
Determining Preclinical Safety of Aclarubicin in Pediatric MalignanciesDarleen S Tu, Aaron K Olson, Kimberly S Waggie, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 13, 2014
Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomasHsueh-Li Tan, Michael C Haffner, David M Esopi, et al.
The Prostate|August 17, 2021
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancerMichael C Haffner, Akshay Bhamidipati, Harrison K Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate CancerDiana C DeLucia, Thomas M Cardillo, Lisa Ang, et al.
Pageof 17

Showing results (101-110 of 169) with videos related to

Sort By:
Pageof 17
Journal of the National Cancer Institute|November 20, 2024
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabelingYibai Zhao, Roman Gulati, Zhenwei Yang, et al.
The American Journal of Pathology|October 29, 2022
Genomic Characterization of Prostatic Basal Cell CarcinomaJin-Yih Low, Minjeong Ko, Brian Hanratty, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Determining preclinical safety of Aclarubicin in pediatric malignanciesDarleen S Tu, Aaron K Olson, Kimberly S Waggie, et al.
Cancer Research Communications|December 19, 2023
FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-genomic Features of Prostate CancerOluwademilade Dairo, Lia DePaula Oliveira, Ethan Schaffer, et al.
Molecular Cancer Research : MCR|October 16, 2019
Functional Loss of <i>ATRX</i> and <i>TERC</i> Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer CellsMindy K Graham, Jiyoung Kim, Joseph Da, et al.
The Journal of Clinical Investigation|October 19, 2013
Tracking the clonal origin of lethal prostate cancerMichael C Haffner, Timothy Mosbruger, David M Esopi, et al.
Pediatric Blood & Cancer|November 27, 2025
Determining Preclinical Safety of Aclarubicin in Pediatric MalignanciesDarleen S Tu, Aaron K Olson, Kimberly S Waggie, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 13, 2014
Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomasHsueh-Li Tan, Michael C Haffner, David M Esopi, et al.
The Prostate|August 17, 2021
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancerMichael C Haffner, Akshay Bhamidipati, Harrison K Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate CancerDiana C DeLucia, Thomas M Cardillo, Lisa Ang, et al.
Pageof 17